Kingston Financial Newsletter | hutchmed (china) (00013) announced that after FRUZAQLA (Fruquintinib) 1 mg/5 mg capsules obtained pricing approval in Japan and was commercially launched by its partner Takeda (TSE: 4502/NYSE: TAK) for the treatment of treated metastatic colorectal cancer patients, hutchmed (china) will receive a milestone payment. Previously, FRUZAQLA had obtained production and sales approval from Japan's Ministry of Health, Labour and Welfare (MHLW).
FRUZAQLA is the first oral innovative targeted therapy approved for the treatment of metastatic colorectal cancer in Japan in over a decade, regardless of the patients' biomarker status. FRUZAQLA is approved for the treatment of advanced or recurrent colorectal cancer that cannot be completely cured or removed and has progressed after chemotherapy. According to statistics from the National Cancer Center Japan, colorectal cancer is the most common type of cancer in Japan, with an estimated 0.161 million new cases and 0.054 million deaths in 2023.
